Sagent Pharmaceuticals of Schaumberg, Illinois raised $40 million in two tranches of a series B financing from China sources. Zhejiang Hisun Pharmaceutical invested $10 million, which we reported earlier, and the remaining $30 million was contributed by an unnamed China-focused private equity investment fund. Sagent is building a large portfolio of generic injectable products that are “high quality, low cost,” using a global network of partners. More details...

Stock Symbol: (SHA: 600267)